[go: up one dir, main page]

GB0202254D0 - Prevention of scarring - Google Patents

Prevention of scarring

Info

Publication number
GB0202254D0
GB0202254D0 GBGB0202254.9A GB0202254A GB0202254D0 GB 0202254 D0 GB0202254 D0 GB 0202254D0 GB 0202254 A GB0202254 A GB 0202254A GB 0202254 D0 GB0202254 D0 GB 0202254D0
Authority
GB
United Kingdom
Prior art keywords
scarring
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202254.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Priority to GBGB0202254.9A priority Critical patent/GB0202254D0/en
Publication of GB0202254D0 publication Critical patent/GB0202254D0/en
Priority to JP2003563565A priority patent/JP2005523263A/en
Priority to EP20030734608 priority patent/EP1469857A1/en
Priority to BR0307410-2A priority patent/BR0307410A/en
Priority to CA002474852A priority patent/CA2474852A1/en
Priority to PCT/IB2003/000134 priority patent/WO2003063875A1/en
Priority to MXPA04007430A priority patent/MXPA04007430A/en
Priority to US10/350,933 priority patent/US20030216407A1/en
Priority to TW092101618A priority patent/TW200302105A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0202254.9A 2002-01-31 2002-01-31 Prevention of scarring Ceased GB0202254D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring
JP2003563565A JP2005523263A (en) 2002-01-31 2003-01-21 Use of PDE5 inhibitors in the treatment of scarring and fibrosis
EP20030734608 EP1469857A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
BR0307410-2A BR0307410A (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of healing and fibrosis
CA002474852A CA2474852A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
PCT/IB2003/000134 WO2003063875A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
MXPA04007430A MXPA04007430A (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis.
US10/350,933 US20030216407A1 (en) 2002-01-31 2003-01-24 Use of PDE5 inhibitors in the treatment of scarring
TW092101618A TW200302105A (en) 2002-01-31 2003-01-24 Use of PDE5 inhibitors in the treatment of scarring

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring

Publications (1)

Publication Number Publication Date
GB0202254D0 true GB0202254D0 (en) 2002-03-20

Family

ID=9930135

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202254.9A Ceased GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring

Country Status (8)

Country Link
EP (1) EP1469857A1 (en)
JP (1) JP2005523263A (en)
BR (1) BR0307410A (en)
CA (1) CA2474852A1 (en)
GB (1) GB0202254D0 (en)
MX (1) MXPA04007430A (en)
TW (1) TW200302105A (en)
WO (1) WO2003063875A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528229A (en) * 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Composition containing PDE4 inhibitor and PDE5 inhibitor
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
DE602004022463D1 (en) * 2004-08-19 2009-09-17 Switch Biotech Llc Use of a PDE5 inhibitor for the treatment and prevention of hypopigmentation disorders
WO2006018088A1 (en) * 2004-08-19 2006-02-23 Switch Biotech Ag Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
EP1838319B1 (en) * 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
DE102005001989A1 (en) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenous formulations of PDE inhibitors
WO2006111198A1 (en) * 2005-04-18 2006-10-26 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease
EP1888074B1 (en) * 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
AR079451A1 (en) 2009-12-18 2012-01-25 Nycomed Gmbh COMPOUNDS 3,4,4A, 10B-TETRAHIDRO-1H-TIOPIRANO [4,3-C] ISOQUINOLINA
CN102970965A (en) * 2010-04-05 2013-03-13 Sk化学公司 Composition containing PDE5 inhibitor for relieving skin wrinkles
HUE025162T2 (en) 2010-05-26 2016-04-28 Adverio Pharma Gmbh Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc).
EP2753332B1 (en) * 2011-09-09 2017-02-15 SK Chemicals Co., Ltd. Mridenafil for reducing skin wrinkles
AT512084A1 (en) 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
EP2992885A3 (en) * 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
EP3595623B1 (en) 2017-03-14 2024-05-01 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
EP3595622B1 (en) 2017-03-14 2023-01-11 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
CN112773898A (en) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 Application of phosphodiesterase 5 inhibitor in preparing anti-fibrosis disease medicine
CA3229274A1 (en) * 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
AU5067098A (en) * 1997-11-26 1999-06-15 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives with cgmp-pde inhibitory activity
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Also Published As

Publication number Publication date
MXPA04007430A (en) 2005-06-20
BR0307410A (en) 2004-12-28
EP1469857A1 (en) 2004-10-27
CA2474852A1 (en) 2003-08-07
TW200302105A (en) 2003-08-01
JP2005523263A (en) 2005-08-04
WO2003063875A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
HK1077762A1 (en) INHIBITORS OF TFGβ
EG25482A (en) Inhibitors
HK1080745A1 (en) Angiogenesis inhibitors
GB0202254D0 (en) Prevention of scarring
AU2003236991A8 (en) Representations of processes
EP1511488A4 (en) Human adam-10 inhibitors
IL175603A0 (en) Reduction of dermal scarring
EP1532133A4 (en) Nf-:b inhibitors
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
TWI367754B (en) New carboxamide compound
AU2003262141A8 (en) Preperation of desloratatine
AU2003298725A8 (en) Preparation of metallotexaphyrins
GB0224049D0 (en) Removal of nitrogen compounds
PL356853A1 (en) Application of bacteriphages
SI1537210T1 (en) Decoy-oligonucleotide-inhbition of cd40-expression
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
AU2003215235A8 (en) Cks1 inhibitors
AU2003280609A1 (en) Alpha-GLUCOSIDASE INHIBITOR
HU0104370D0 (en) Honeyed schnaps of oerseg
TW567775U (en) Structure of hairtie
AU2003292925A8 (en) Polymerization of phosphaalkenes
TW587476U (en) Improved structure of spinning-top
IL158677A0 (en) Uses of atrx
TW533774U (en) Structure improvement of flyswatter

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)